Income Statement

The income statement presents information on the financial results of a company business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue.

Allergan PLC, consolidated income statement

US$ in thousands

12 months ended:	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
Net revenues	16,088,900)	15,787,400)	15,940,700)	14,570,600)	15,071,000)
Cost of sales, excludes amortization and impairment of acquired intangibles including product rights	(2,493,100)	(2,191,400)	(2,168,000)	(1,860,800)	(4,810,400)
Gross profit	13,595,800)	13,596,000)	13,772,700)	12,709,800)	10,260,600)
Research and development	(1,812,000)	(2,266,200)	(2,100,100)	(2,575,700)	(2,358,500)
Selling and marketing	(3,461,700)	(3,250,600)	(3,514,800)	(3,266,400)	(2,914,000)
General and administrative	(2,481,800)	(1,271,200)	(1,501,900)	(1,473,900)	(1,765,600)
Amortization	(5,856,600)	(6,552,300)	(7,197,100)	(6,470,400)	(5,453,400)
Goodwill impairments	(3,552,800)	(2,841,100)	—)	—)	—)
In-process research and development impairments	(436,000)	(804,600)	(1,452,300)	(743,900)	(511,600)
Asset sales and impairments, net	(440,200)	(2,857,600)	(3,927,700)	(5,000)	(272,000)
Operating loss	(4,445,300)	(6,247,600)	(5,921,200)	(1,825,500)	(3,014,500)
Interest income	76,800)	45,200)	67,700)	69,900)	11,400)
Interest expense	(783,000)	(911,200)	(1,095,600)	(1,295,600)	(1,193,300)
Teva Share Activity	—)	60,900)	(3,269,300)	—)	—)
Sale of businesses	—)	182,600)	—)	—)	—)
Debt extinguishment costs as part of the debt tender offer	—)	—)	(161,600)	—)	—)
Debt extinguishment other	(200)	15,600)	(27,600)	—)	—)
Other-than-temporary impairments	—)	—)	(26,100)	—)	—)
Dividend income	—)	—)	85,200)	68,200)	—)
Naurex recovery	—)	—)	20,000)	—)	—)
Forward sale of Teva shares	—)	—)	(62,900)	—)	—)
Pfizer termination fee, Allergan plc only	—)	—)	—)	150,000)	—)
Bridge loan commitment fee	—)	—)	—)	—)	(264,900)
Interest rate lock	—)	—)	—)	—)	31,000)
Other	33,000)	(2,400)	5,000)	1,000)	100)
Other income (expense), net	32,800)	256,700)	(3,437,300)	219,200)	(233,800)
Loss before income taxes and noncontrolling interest	(5,118,700)	(6,856,900)	(10,386,400)	(2,832,000)	(4,430,200)
(Provision) benefit for income taxes	(146,400)	1,770,700)	6,670,400)	1,897,000)	1,561,900)
Net loss from continuing operations, net of tax	(5,265,100)	(5,086,200)	(3,716,000)	(935,000)	(2,868,300)
Income (loss) from discontinued operations, net of tax	—)	—)	(402,900)	15,914,500)	6,787,700)
Net income (loss)	(5,265,100)	(5,086,200)	(4,118,900)	14,979,500)	3,919,400)
Income attributable to noncontrolling interest	(5,900)	(10,200)	(6,600)	(6,100)	(4,200)
Net income (loss) attributable to shareholders	(5,271,000)	(5,096,400)	(4,125,500)	14,973,400)	3,915,200)
Dividends on preferred shares	—)	(46,400)	(278,400)	(278,400)	(232,000)
Net income (loss) attributable to ordinary shareholders	(5,271,000)	(5,142,800)	(4,403,900)	14,695,000)	3,683,200)

Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).

Download chart

Allergan PLC (NYSE:AGN)

Income Statement